Aerie Pharmaceuticals (AERI)- Prohost Biotech

Tag: Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals Is Speeding Towards Improving the Magement of Glaucoma

AERIE PHARMACEUTICALS (AERI) A YOUNG BUT STRONG COMPETITOR IN THE GLAUCOMA HUGE MARKET - Aerie Pharmaceuticals has eye drops that could become a game changer in the management of glaucoma. - The firm’s lead drug, Rhopressa™, is a one drop...

February 11, 2015

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of a Promising Glaucoma Drug

Aerie Pharmaceuticals (AERI) , which is specialized in glaucoma treatments reported successful results of its second Phase 3 trial for Rhopressa™ — a novel once-daily, triple-action eye drops for glaucoma . The trial achieved its primary efficacy endpoint demonstrating non-inferiority...

September 17, 2015

AERIE Pharmaceuticals: The Novel Glaucoma Eye Drops Confirm Their Superiority

On February 4, 2015, we wrote an article titled, “Aerie Pharmaceuticals is speeding towards improving the treatment of glaucoma”, posted under News & Comments at the Prohost website, we wrote the following: YOUNG BUT STRONG COMPETITOR IN THE GLAUCOMA HUGE...

February 18, 2016

Amgen: Positive Data from Osteoporosis Trial. Aerie Pharmaceuticals: More Data on Glaucoma Drug Safety.

Amgen (AMGN) and UCB (Euronext Brussels: UCB) announced positive results from the BRIDGE pivotal Phase 3 placebo-controlled study evaluating the efficacy and safety of romosozumab in treating men with osteoporosis. The study met the primary endpoint, demonstrating a statistically significant increase...

March 22, 2016

Aerie Pharmaceuticals Is Speeding Towards Improving the Magement of Glaucoma

February 11, 2015

Why Aerie Pharmaceuticals' Stock Rallied Today. What About Now?

As we expected in our previous articles, Today, Aerie Pharmaceuticals (AERI) came up with great news about its glaucoma treatment. The stock surged …. On February 18, 2016, Under News & Comments, we wrote an article titled “ Aerie...

September 15, 2016

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of a Promising Glaucoma Drug

September 17, 2015

Prohost Letter #400

Prohost Letter #400 NEAR-TERM INVESTING Th e Pro h os t L e tt e r # 39 9 Pa r t 3 ha s P ro m i se d t o D es c ri b e t...

October 27, 2016

AERIE Pharmaceuticals: The Novel Glaucoma Eye Drops Confirm Their Superiority

February 18, 2016

Amgen: Positive Data from Osteoporosis Trial. Aerie Pharmaceuticals: More Data on Glaucoma Drug Safety.

March 22, 2016

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024